RGNX
HEALTHCARERegenxbio Inc
$10.22+1.00 (+10.85%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RGNX Today?
No stock-specific AI insight has been generated for RGNX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.23$16.19
$10.22
Fundamentals
Market Cap$528M
P/E Ratio—
EPS$-3.76
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin-1.1%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding51.6M
RGNX News
36 articles- REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual MeetingYahoo Finance·May 7, 2026
- EyePoint (EYPT) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 6, 2026
- REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular DystrophyYahoo Finance·May 6, 2026
- OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts AheadYahoo Finance·Apr 22, 2026
- Ocugen Stock Outlook: Valuation, Cash Runway and Dilution RiskYahoo Finance·Apr 22, 2026
- REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXBenzinga·Apr 15, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNXGlobeNewswire Inc.·Apr 14, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APEGlobeNewswire Inc.·Apr 14, 2026
- REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Apr 12, 2026
- Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 6, 2026
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmBenzinga·Apr 6, 2026
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Apr 5, 2026
- TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPCGlobeNewswire Inc.·Apr 5, 2026
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Apr 5, 2026
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the FirmGlobeNewswire Inc.·Apr 3, 2026
- ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNOWGlobeNewswire Inc.·Apr 1, 2026
- Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.Yahoo Finance·Apr 1, 2026
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Mar 30, 2026
- REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXBenzinga·Mar 30, 2026
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmBenzinga·Mar 30, 2026
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Franklin BSP Realty Trust, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRTGlobeNewswire Inc.·Mar 26, 2026
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Mar 26, 2026
- Denali Jumps, Pulling Regenxbio Higher, On Early FDA ApprovalYahoo Finance·Mar 25, 2026
- Mixed signals cloud the orphan drug marketPharmavoice·Mar 25, 2026
- Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage DataYahoo Finance·Mar 20, 2026
- OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To WatchYahoo Finance·Mar 20, 2026
- REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202Yahoo Finance·Mar 11, 2026
- uniQure stock surges 36% on FDA official’s departureYahoo Finance·Mar 9, 2026
- REGENXBIO Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ResilienceYahoo Finance·Mar 5, 2026
- REGENXBIO Inc. Q4 2025 Earnings Call SummaryMoby·Mar 5, 2026
- Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 5, 2026
- Regenxbio: Q4 Earnings SnapshotYahoo Finance·Mar 5, 2026
- REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsYahoo Finance·Mar 5, 2026
- REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceYahoo Finance·Mar 4, 2026
- MAHA Is Bringing Chaos to Biotech Investment Beyond Just VaccinesWall Street Journal·Mar 3, 2026
All 36 articles loaded
Price Data
Open$9.35
Previous Close$9.22
Day High$10.40
Day Low$9.30
52 Week High$16.19
52 Week Low$7.23
52-Week Range
$7.23$16.19
$10.22
Fundamentals
Market Cap$528M
P/E Ratio—
EPS$-3.76
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin-1.1%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding51.6M
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—